Drugs targeting intracellular molecule: JAK inhibitor and syk inhibitor

Kunihiro Yamaoka; Kazuyoshi Saito; Yoshiya Tanaka

doi:10.3999/jscpt.44.23

Drugs targeting intracellular molecule: JAK inhibitor and syk inhibitor

Kunihiro Yamaoka, Kazuyoshi Saito, Yoshiya Tanaka

Department of Internal Medicine

Research output: Contribution to journal › Review article › peer-review

Abstract

Biologies targeting TNF-a and IL-6 have dramatically changed the treatment of rheumatoid arthritis (RA). Previously the therapeutic aim was to control the symptoms of arthritis. However, today our treatment goal is to achieve remission. Inflammatory cytokines involved in the pathology of RA activate multiple signaling pathways in the cytoplasm. Hence, regulating these intracellular signaling pathways has been expected to achieve similar treatment effects as biologies on RA. Recent clinical trials with compounds targeting Janus kinase (JAK) or spleen tyrosine kinase (Syk) have demonstrated high clinical efficacy resembling the biologies. Here we overview the development process of these inhibitors together with the results of clinical trials.

Original language	English
Pages (from-to)	23-27
Number of pages	5
Journal	Japanese Journal of Clinical Pharmacology and Therapeutics
Volume	44
Issue number	1
DOIs	https://doi.org/10.3999/jscpt.44.23
Publication status	Published - 2013 Jan 1

Keywords

JAK
Rheumatoid arthritis
Syk

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.3999/jscpt.44.23

Cite this

@article{3d240bf8eaf146da92c48dde5e10afa6,

title = "Drugs targeting intracellular molecule: JAK inhibitor and syk inhibitor",

abstract = "Biologies targeting TNF-a and IL-6 have dramatically changed the treatment of rheumatoid arthritis (RA). Previously the therapeutic aim was to control the symptoms of arthritis. However, today our treatment goal is to achieve remission. Inflammatory cytokines involved in the pathology of RA activate multiple signaling pathways in the cytoplasm. Hence, regulating these intracellular signaling pathways has been expected to achieve similar treatment effects as biologies on RA. Recent clinical trials with compounds targeting Janus kinase (JAK) or spleen tyrosine kinase (Syk) have demonstrated high clinical efficacy resembling the biologies. Here we overview the development process of these inhibitors together with the results of clinical trials.",

keywords = "JAK, Rheumatoid arthritis, Syk",

author = "Kunihiro Yamaoka and Kazuyoshi Saito and Yoshiya Tanaka",

year = "2013",

month = jan,

day = "1",

doi = "10.3999/jscpt.44.23",

language = "English",

volume = "44",

pages = "23--27",

journal = "Japanese Journal of Clinical Pharmacology and Therapeutics",

issn = "0388-1601",

publisher = "Japanese Society of Clinical Pharmacology and Therapeutics",

number = "1",

}

TY - JOUR

T1 - Drugs targeting intracellular molecule

T2 - JAK inhibitor and syk inhibitor

AU - Yamaoka, Kunihiro

AU - Saito, Kazuyoshi

AU - Tanaka, Yoshiya

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Biologies targeting TNF-a and IL-6 have dramatically changed the treatment of rheumatoid arthritis (RA). Previously the therapeutic aim was to control the symptoms of arthritis. However, today our treatment goal is to achieve remission. Inflammatory cytokines involved in the pathology of RA activate multiple signaling pathways in the cytoplasm. Hence, regulating these intracellular signaling pathways has been expected to achieve similar treatment effects as biologies on RA. Recent clinical trials with compounds targeting Janus kinase (JAK) or spleen tyrosine kinase (Syk) have demonstrated high clinical efficacy resembling the biologies. Here we overview the development process of these inhibitors together with the results of clinical trials.

AB - Biologies targeting TNF-a and IL-6 have dramatically changed the treatment of rheumatoid arthritis (RA). Previously the therapeutic aim was to control the symptoms of arthritis. However, today our treatment goal is to achieve remission. Inflammatory cytokines involved in the pathology of RA activate multiple signaling pathways in the cytoplasm. Hence, regulating these intracellular signaling pathways has been expected to achieve similar treatment effects as biologies on RA. Recent clinical trials with compounds targeting Janus kinase (JAK) or spleen tyrosine kinase (Syk) have demonstrated high clinical efficacy resembling the biologies. Here we overview the development process of these inhibitors together with the results of clinical trials.

KW - JAK

KW - Rheumatoid arthritis

KW - Syk

UR - http://www.scopus.com/inward/record.url?scp=84874254927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874254927&partnerID=8YFLogxK

U2 - 10.3999/jscpt.44.23

DO - 10.3999/jscpt.44.23

M3 - Review article

AN - SCOPUS:84874254927

SN - 0388-1601

VL - 44

SP - 23

EP - 27

JO - Japanese Journal of Clinical Pharmacology and Therapeutics

JF - Japanese Journal of Clinical Pharmacology and Therapeutics

IS - 1

ER -

Drugs targeting intracellular molecule: JAK inhibitor and syk inhibitor

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this